Evidence map›Paper›PMID 33214672›Full record

ArticlePediatric research2021

Effect of digestion on stability of palivizumab IgG1 in the infant gastrointestinal tract.

Jiraporn Lueangsakulthai, Bum Jin Kim, Veronique Demers-Mathieu, Baidya Nath P Sah, Yeonhee Woo, Amy Olyaei, Molly Aloia, Ann O'Connor, Brian P Scottoline, David C Dallas

Abstract read
PubMed Publisher
In one paragraph

Article in Pediatric research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jiraporn LueangsakulthaiNutrition Program, School of Biological and Population Health Sciences, College of Public Health and Human Sciences, Oregon State University, Corvallis, OR, USA.
Bum Jin KimNutrition Program, School of Biological and Population Health Sciences, College of Public Health and Human Sciences, Oregon State University, Corvallis, OR, USA.
Veronique Demers-MathieuNutrition Program, School of Biological and Population Health Sciences, College of Public Health and Human Sciences, Oregon State University, Corvallis, OR, USA.
Baidya Nath P SahNutrition Program, School of Biological and Population Health Sciences, College of Public Health and Human Sciences, Oregon State University, Corvallis, OR, USA.
Yeonhee WooDivision of Neonatology, Department of Pediatrics, Oregon Health and Science University, Portland, OR, USA.
Amy OlyaeiDivision of Neonatology, Department of Pediatrics, Oregon Health and Science University, Portland, OR, USA.
Molly AloiaDivision of Neonatology, Department of Pediatrics, Oregon Health and Science University, Portland, OR, USA.
Ann O'ConnorDivision of Neonatology, Department of Pediatrics, Oregon Health and Science University, Portland, OR, USA.
Brian P ScottolineDivision of Neonatology, Department of Pediatrics, Oregon Health and Science University, Portland, OR, USA.
David C DallasNutrition Program, School of Biological and Population Health Sciences, College of Public Health and Human Sciences, Oregon State University, Corvallis, OR, USA. Dave.Dallas@oregonstate.edu.

Funding

Orbitrap Elite with ETDS10OD020111 · OD · OREGON STATE UNIVERSITY · PI MAIER, CLAUDIA S · 2015 to 2015
$600k
NIH HHS S10 OD020111
6 · The paper itself

Abstract

backgroundPotentially, orally administered antibodies specific to enteric pathogens could be administered to infants to prevent diarrheal infections, particularly in developing countries where diarrhea is a major problem. However, to prevent infection, such antibodies would need to resist degradation within the gastrointestinal tract.

methodsPalivizumab, a recombinant antibody specific to respiratory syncytial virus (RSV), was used in this study as a model for examining the digestion of neutralizing antibodies to enteric pathogens in infants. The survival of this recombinant IgG1 across digestion in 11 infants was assayed via an anti-idiotype ELISA and RSV F protein-specific ELISA. Concentrations were controlled for any dilution or concentration that occurred in the digestive system using mass spectrometry-based quantification of co-administered, orally supplemented, indigestible polyethylene glycol (PEG-28).

resultsBinding activity of Palivizumab IgG1 decreased (26-99%) across each phase of in vivo digestion as measured by both anti-idiotype and RSV F protein-specific ELISAs.

conclusionAntibodies generated for passive protection of the infant gastrointestinal tract from pathogens will need to be more resistant to digestion than the model antibody fed to infants in this study, or provided in higher doses to be most effective. IMPACT: Binding activity of palivizumab IgG1 decreased (26-99%) across each phase of in vivo infant digestion as measured by both anti-idiotype and RSV F protein-specific ELISAs. Palivizumab was likely degraded by proteases and changes in pH introduced in the gut. Antibodies generated for passive protection of the infant gastrointestinal tract from pathogens will need to be more resistant to digestion than the model antibody fed to infants in this study, or provided in higher doses to be most effective. The monoclonal antibody IgG1 tested was not stable across the infant gastrointestinal tract. The observation of palivizumab reduction was unlikely due to dilution in the gastrointestinal tract. The results of this work hint that provision of antibody could be effective in preventing enteric pathogen infection in infants. Orally delivered recombinant antibodies will need to either be dosed at high levels to compensate for digestive losses or be engineered to better resist digestion. Provision of enteric pathogen-specific recombinant antibodies to at-risk infants could provide a new and previously unexplored pathway to reducing the infection in infants. The strategy of enteric recombinant antibodies deserves more investigation throughout medicine as a novel means for treatment of enteric disease targets.

Indexed as

DigestionAdministration, OralAntibodies, NeutralizingAntibodies, ViralAntiviral AgentsDrug StabilityEnzyme-Linked Immunosorbent AssayFemaleGastrointestinal TractHost-Pathogen InteractionsHumansInfant, NewbornMalePalivizumabProtein StabilityRespiratory Syncytial VirusesAntibodies, NeutralizingAntibodies, ViralAntiviral AgentsPalivizumab

Identifiers

PMID33214672

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.